@article{57eabb6617e24433b2276f95385f49ec,
title = "Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group",
keywords = "adjuvant, bevacizumab, colon cancer, FOLFOX, XELOX, OPEN-LABEL, STAGE-II, OXALIPLATIN, FLUOROURACIL, LEUCOVORIN, IRINOTECAN, TRIAL, CHEMOTHERAPY, CAPECITABINE, CARCINOMA, 3122 Cancers",
author = "T. Andre and D. Vernerey and Im, \{S. A.\} and G. Bodoky and R. Buzzoni and S. Reingold and F. Rivera and J. McKendrick and W. Scheithauer and G. Ravit and G. Fountzilas and Yong, \{W. P.\} and R. Isaacs and P. {\"O}sterlund and Liang, \{J. T.\} and Creemers, \{G. J.\} and M. Rakez and \{Van Cutsem\}, E. and D. Cunningham and J. Tabernero and \{de Gramont\}, A.",
year = "2020",
month = feb,
doi = "10.1016/j.annonc.2019.12.006",
language = "English",
volume = "31",
pages = "246--256",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Elsevier Ltd. ",
number = "2",
}